High dose of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts and generates regulatory cells

Transplantation

Volumn 75, Issue 2, 2003, Pages 217-220

  Aramaki, Osamu ^a,b   Takayama, Tadatoshi ^a   Yokoyama, Takeshi ^a   Takano, Seigo ^a   Akiyama, Yoshinobu ^c   Shibutani, Shintaro ^c   Matsumoto, Kenji ^c   Shimazu, Motohide ^c   Kitajima, Masaki ^c   Ikeda, Yoshifumi ^b   Shirasugi, Nozomu ^b   Niimi, Masanori ^b  

^a NIHON UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTICOAGULANT AGENT; ANTITHROMBIN III; IMMUNOMODULATING AGENT; INTERLEUKIN 2;

ACUTE GRAFT REJECTION; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT SURVIVAL; HEART GRAFT; HISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ANTITHROMBIN III; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTERLEUKIN-2; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037467795     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000041781.94679.A1     Document Type: Article

References (10)

1. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 1989; 87: 2S.
2. Diaz-Cremades JM, Lorenzo R, Sanchez M, et al. Use of antithrombin III in critical patients. Intensive Care Med 1994; 20: 577.
3. Hashikura Y, Kawasaki S, Okumura N, et al. Prevention of hepatic artery thrombosis in pediatric liver transplantation. Transplantation 1995; 60: 1109.
4. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995; 32: 19.
5. Yang X, Ma N, Szabolcs MJ, et al. Upregulation of COX-2 during cardiac allograft rejection. Circulation 2000; 101: 430.
6. Shaw JF. Prolongation of rat cardiac allograft survival by treatment with prostacyclin or aspirin during acute rejection. Transplantation 1983; 35: 526.
7. Braun C, Schultz M, Fang L, et al. Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin). Transplantation 2001; 72: 209.
8. Niimi M, Shirasugi N, Hamano K, et al. Oral delivery of xeno-antigen combined with non-depleting anti-CD4 monoclonal antibody induces significantly prolonged survival of concordant skin xenograft. Xeno-transplantation 2001; 8: 75.
9. Takeshita K, Arakawa K, Okamoto M, et al. The anticoagulant effect of antithrombin III on hyperacute xenograft rejection. Transplant Proc 1996; 28: 631.
10. Zuo XJ, Nicolaidou E, Okada Y, et al. Antithrombin III inhibits lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, gamma-IFN and IL-4) in vitro. Transpl Immunol 2001; 9: 1.